Lantern Pharma highlights ‘promising’ prelinical results of LP-184

Lantern Pharma announced a significant advancement demonstrating the preclinical synergy of LP-184 with checkpoint inhibitors and the ability of LP-184 to resensitize tumors that have become non-responsive to Anti-PD1 therapies. The company will be presenting preliminary data from the recent work done in conjunction with Drs. Yong Du and Shiaw-Yih Lin at MD Anderson at The Immuno-Oncology Summit 2024 in Philadelphia. The data will be presented in the form of poster entitled, LP-184, a Novel Acylfulvene, Sensitizes Immuno-Refractory Triple Negative Breast Cancers To Anti-PD1 Therapy by Affecting the Tumor Microenvironment. The poster highlights the following key points: LP-184 seems to potentiate anti-PD1 response in a mouse model of TNBC that is non-hypermutated and resistant to immunotherapy in the absence of LP-184. LP-184 can potentially transform immunologically “cold” tumors into “hot” tumors by modulating T cell activity in the tumor microenvironment and inducing a replication stress response defect. LP-184 seems to reshape the tumor microenvironment by significantly reducing the amount of M2 macrophages – which are associated with tumor drug resistance, tumor cell proliferation and are involved in helping the tumor cells escape immune cell death. LP-184 combined with an anti-PD1 agent elicited a greater anti-tumor response than monotherapies in mouse TNBC tumors that are non-hypermutated and resistant to immune checkpoint inhibitors LP-184 is being investigated in an ongoing first-in-human Phase 1 trial in advanced recurrent solid tumors to establish a maximum tolerated dose and assess its overall safety and suitability in more targeted cancer indications, including TNBC.